ID: ALA2298868

Max Phase: Preclinical

Molecular Formula: C25H21ClN4O5S

Molecular Weight: 524.99

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(C2C(Cl)C(=O)N2NC(=O)NCC(=O)N2c3ccccc3Sc3ccccc32)ccc1O

Standard InChI:  InChI=1S/C25H21ClN4O5S/c1-35-18-12-14(10-11-17(18)31)23-22(26)24(33)30(23)28-25(34)27-13-21(32)29-15-6-2-4-8-19(15)36-20-9-5-3-7-16(20)29/h2-12,22-23,31H,13H2,1H3,(H2,27,28,34)

Standard InChI Key:  MJZKXVWWMUBNQF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 524.99

Molecular Weight (Monoisotopic): 524.0921

AlogP: 3.94

#Rotatable Bonds: 5

Polar Surface Area: 111.21

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.28

CX Basic pKa:

CX LogP: 3.04

CX LogD: 3.04

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.34

Np Likeness Score: -0.42

References

1. Rajasekaran A, Devi KS.  (2013)  Synthesis and biological evaluation of 1-(3-chloro-2-oxo-4-phenylazetidin-1-yl)-3-(2-oxo-2-(10H-phenothiazin-10-yl)ethyl)urea derivatives,  22  (6): [10.1007/s00044-012-0255-z]

Source

Source(1):

• Scientific Literature